Arcline sells Akron Bio to MaxCyte for $151.8 million

MaxCyte, Nasdaq-listed cell-engineering company, has entered into a definitive agreement to acquire Akron BioProducts, known as Akron Bio, from affiliates of Arcline Investment Management for total consideration of $151.8 million. The transaction is expected to close before the end of 2026, subject to customary conditions.

Akron Bio, headquartered in Boca Raton, Florida, supplies GMP-grade reagents and ancillary materials used across the cell therapy manufacturing workflow, including its Closed System Solutions line. Its products include cytokines, growth factors, human plasma-derived products and media. Akron is expected to generate about $28 million in revenue and $7-8 million in EBITDA in 2026.

MaxCyte will pay $105.0 million in cash, 20,639,733 common shares valued at about $26.8 million, and $20.0 million in deferred payments due in January 2028 and January 2029. It secured a credit facility of up to $75.0 million from MidCap Financial. Stifel and Sidley Austin LLP advised MaxCyte, while Jefferies LLC and two law firms advised Arcline.